dlbcl updates at ash 2021
Published 2 years ago • 640 plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
1:04
updates in dlbcl from ash 2021
-
3:48
looking forward to ash 2021: key updates in dlbcl
-
1:58
ash highlights: glofitamab in dlbcl & pirtobrutinib and epcoritamab in richter's transformation
-
4:31
updates in bispecifics for dlbcl from ash: glofitamab, odronextamab, epcoritamab & mosunetuzumab
-
3:02
exciting aml updates at ash 2020
-
1:23
ash 2021: key upcoming data
-
1:32
aml data at ash 2021 and implications on clinical practice
-
1:02
the changing standard of care in dlbcl
-
29:38
dlbcl treatment approaches: what you need to know
-
6:38
gilteritinib plus venetoclax for r/r flt3-mutated aml
-
10:09
understanding diffuse large b-cell lymphoma with jennifer amengual, md
-
2:09
trends in aml and mds at ash 2021
-
2:57
lymphoma highlights from ash 2021
-
4:40
all at ash: four key updates
-
1:01
novel treatment paradigms for aml at ash 2021
-
1:08
cml news to look out for at ash 2021
-
0:41
ash 2021 highlights in cml
-
3:04
applying molecular understanding of dlbcl to management strategies
-
2:09
ash highlights in cll: moving towards fixed-duration treatment, the role of mrd & alpine results
-
8:42
updates in the aml field at ash 2020
-
0:42
targeted therapies for dlbcl treatment
-
1:18
hodgkin lymphoma highlights at ash 2022 and future outlooks